IP Library Granted Patent US 10,507,190
Granted Patent B2
US 10,507,190 · App. 16/019,690 · Granted Dec 17, 2019

Method for treating hyperhidrosis with dexmecamylamine

Inventor: Merouane Bencherif (Winston-Salem, NC)
Assignee: Atacama Therapeutics, Inc.
A61K31/13A61K9/0053A61K9/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,507,190
App. No.
16/019,690
Granted
Dec 17, 2019
Kind
B2
Abstract

The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of hyperhidrosis.

Claims (18)

1. A method of treating hyperhidrosis, the method comprising the administration of a therapeutically effective amount of dexmecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, to a subject with hyperhidrosis.

2. The method of claim 1 , wherein the administration of dexmecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine, is once daily.

3. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 4 mg.

4. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 0.5 mg.

5. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 1.0 mg.

6. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 2.0 mg.

7. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in tablet form.

8. The method of claim 1 , wherein the administration of dexmecamylamine is sufficient to affect sweating in a patient in at least one location with an Hyperhidrosis Disease Severity Scale change of ≥1.

9. The method according to claim 8 , wherein the administration of dexmecamylamine is sufficient to affect sweating in a patient in at least two locations with an HDSS change of ≥0.5, in each location.

10. The method according to claim 8 , wherein the location is selected from axillary, palmoplantar, face/scalp, or generalized.

11. The method according to claim 1 , wherein the hyperhidrosis is primary hyperhidrosis.

12. The method according to claim 1 , wherein the subject is a human.

13. The method of claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is administered more than once daily.

14. The method of claim 1 , wherein the hyperhidrosis is palmoplantar.

15. The method of claim 6 , wherein the dexmecamylamine or pharmaceutically acceptable salt thereof is administered more than once daily.

16. The method of claim 1 , wherein the hyperhidrosis is secondary hyperhidrosis.

17. The method of claim 1 , wherein the hyperhidrosis is secondary to spinal cord injury.

18. The method of claim 1 , wherein the hyperhidrosis results from increased sympathetic cholinergic activity.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2018
From: CATALYST BIOSCIENCES, INC.
To: ATACAMA THERAPEUTICS, INC.
Reel/Frame 046931/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2018
From: BENCHERIF, MEROUANE
To: TARGACEPT, INC.
Reel/Frame 047118/0761 →
CHANGE OF NAME Recorded Sep 20, 2018
From: TARGACEPT, INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 047118/0810 →
Continuity (3)
Continuation 15505414
Provisional Application 62040477 · Aug 22, 2014
Related Publication 20180369168A1 · Dec 27, 2018